Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 4/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 15/20 | 0.65 |
| ▸ | ATF1 | P18846 | 12/20 | 0.65 |
| ▸ | JUN | P05412 | 4/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.63 |
| ▸ | RELA | Q04206 | 4/20 | 0.63 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864557 | 0.85 | NFKB1 (0.78) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL13077675 | 0.81 | XPO1 (0.69) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL458841 | 0.77 | NFKB1 (1.00) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL4745582 | 0.75 | CNR2 (0.69) | XPO1NFKB1ATF1CNR2 | |
| SCHEMBL1862523 | 0.74 | NFKB1 (0.74) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL3128576 | 0.72 | NFKB1 (0.61) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL10158195 | 0.71 | BACE1 (0.70) | — | |
| SCHEMBL8542065 | 0.71 | ATF1 (0.69) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL2307377 | 0.71 | NFKB1 (0.61) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL6933367 | 0.70 | XPO1 (0.54) | XPO1NFKB1ATF1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | XPO1 1607/4885NFKB1 2117/4885ATF1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.